Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Aptose Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Aptose Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
AdAlta Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
AdAlta 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Osteosarcoma Indication Strategy Report 2026: IGF-1R, HER2, Trials and Deal Outlook
20 July 2026
A 2026 osteosarcoma strategy report covering disease burden, IGF-1R and HER2 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Soft Tissue Sarcoma Indication Strategy Report 2026: MDM2, CDK4, Trials and Deal Outlook
20 July 2026
A 2026 soft tissue sarcoma strategy report covering disease burden, MDM2 and CDK4 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Gastrointestinal Stromal Tumor Indication Strategy Report 2026: KIT, PDGFRA, Trials and Deal Outlook
20 July 2026
A 2026 gastrointestinal stromal tumor strategy report covering disease burden, KIT and PDGFRA biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Anaplastic Thyroid Cancer Indication Strategy Report 2026: BRAF, RET, Trials and Deal Outlook
20 July 2026
A 2026 anaplastic thyroid cancer strategy report covering disease burden, BRAF and RET biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Differentiated Thyroid Cancer Indication Strategy Report 2026: RET, BRAF, Trials and Deal Outlook
20 July 2026
A 2026 differentiated thyroid cancer strategy report covering disease burden, RET and BRAF biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Head and Neck Squamous Cell Carcinoma Indication Strategy Report 2026: PD-1, EGFR, Trials and Deals
20 July 2026
A 2026 head and neck squamous cell carcinoma strategy report covering epidemiology, PD-1 and EGFR biology, clinical competition, deals and portfolio positioning.
Latest Hotspot
8 min read
Nasopharyngeal Carcinoma Indication Strategy Report 2026: PD-1, EGFR, Trials and Deal Outlook
20 July 2026
A 2026 nasopharyngeal carcinoma strategy report covering epidemiology, PD-1 and EGFR biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Mantle Cell Lymphoma Indication Strategy Report 2026: BTK, BCL-2, Trials and Deal Outlook
20 July 2026
A 2026 mantle cell lymphoma strategy report covering disease burden, BTK and BCL-2 biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Patrys Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Patrys 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Amplia Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Amplia Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.